Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01155583 · OUTCOME

Median Progression-free Survival (PFS)

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma · Source last updated 2020-11-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 3 years

What was measured

Median PFS, measured in months from study entry to progression as defined by international response criteria or death of any cause, whichever comes first

Analysis population: Evaluable participants who received treatment

Groups in this outcome

Overall Study - (Azacitidine/Lenalidomide/Dexamethasone)

Participants receive azacitidine subcutaneously once or twice weekly and oral dexamethasone once weekly starting on day 1. Participants also receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses. Participants then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Overall Study - (Azacitidine/Lenalidomide/Dexamethasone)42

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Overall Study - (Azacitidine/Lenalidomide/Dexamethasone)3.1Not reported2.15.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.1
        upper Limit
        5.1
        value
        3.1
denoms
  1. counts
    1. group Id
      OG000
      value
      42
    units
    Participants
description
Median PFS, measured in months from study entry to progression as defined by international response criteria or death of any cause, whichever comes first
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants receive azacitidine subcutaneously once or twice weekly and oral dexamethasone once weekly starting on day 1. Participants also receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses. Participants then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Overall Study - (Azacitidine/Lenalidomide/Dexamethasone)
param Type
MEDIAN
population Description
Evaluable participants who received treatment
reporting Status
POSTED
time Frame
Up to 3 years
title
Median Progression-free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice